Is Overexpression of the Plasma Membrane Transporter (SLC29A4) a New Option to Stratify Patients with High-Risk Neuroblastoma for Treatment with 131I-mIBG?

被引：0
|
作者：
Evers, Raymond [1 ]
机构：
[1] Janssen Pharmaceut, Preclin Sci & Translat Safety, Spring House, PA 19477 USA
来源：
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS | 2023年 / 387卷 / 03期
关键词：
BIOLOGY;
D O I：
10.1124/jpet.123.001875
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：236 / 238
页数：3
相关论文
共 50 条
  • [41] FEASIBILITY/TOXICITY AND RESPONSE OF UPFRONT 131I-MIBG THERAPY FOLLOWED BY STANDARD ARM GPOH NB 2004 PROTOCOL IN NEWLY DIAGNOSED HIGH-RISK NEUROBLASTOMA PATIENTS
    Kraal, K.
    Bleeker, G.
    van Eck-Smit, B.
    van Noesel, M.
    Tytgat, G.
    Caron, H.
    PEDIATRIC BLOOD & CANCER, 2015, 62 : S177 - S177
  • [42] I-131-Meta-Iodobenzylguanidine (MIBG) Therapy Improves Survival in High-Risk Neuroblastoma Patients with MIBG Positive Residual Metastatic Disease
    Simon, T.
    Schmidt, M.
    Decarolis, B.
    Eggert, A.
    Berthold, F.
    Hero, B.
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S33 - S34
  • [43] Feasibility and Efficacy of Treatment Strategy of Tandem High-Dose Chemotherapy and Autologous Stem Cell Transplantation with Incorporation of High-Dose 131I-MIBG Therapy for High-Risk Neuroblastoma
    Shin, J.
    Koh, K. N.
    Suh, J. K.
    Min, S.
    Kim, Y. S.
    Namgoon, J. M.
    Kim, D. Y.
    Ahn, S. D.
    Kim, H.
    Im, H. J.
    Seo, J. J.
    Kook, H.
    PEDIATRIC BLOOD & CANCER, 2019, 66 : S340 - S340
  • [44] Upfront treatment of high-risk neuroblastoma with 131I-MIBG therapy and Topotecan. A phase II pilot window study (AMRO-NB-HR-2000/01)
    van Noesel, Max M.
    Kraal, Kathelijne C. J. M.
    de Kraker, Jan
    van Eck-Smit, Berthe L. F.
    Tytgat, Godelieve A. M.
    Caron, Huib N.
    CANCER RESEARCH, 2014, 74 (20)
  • [45] 131I-MIBG Therapy Combined With High-Dose Chemotherapy as First-Line Treatment Improves Clinical Outcomes in Newly Diagnosed High-Risk Neuroblastoma: Single Institutional Experience
    Kuroda, Rie
    Araki, Raita
    Noguchi, Kazuhiro
    Fujiki, Toshihiro
    Ikawa, Yasuhiro
    Mase, Shintaro
    Fukuda, Masaki
    Wakabayashi, Hiroshi
    Inaki, Anri
    Kayano, Daiki
    Sakai, Seisyo
    Maeba, Hideaki
    Nishimura, Ryosei
    Kinuya, Seigo
    Wada, Taizo
    PEDIATRIC BLOOD & CANCER, 2019, 66 : S108 - S108
  • [46] Sequential treatment of High-risk Neuroblastoma combining I-131 MIBG high-dose and Topotecan. First experience
    Orrego, N.
    Prado-Wohlwend, S.
    Balaguer-Guill, J.
    Torres-Espallardo, I.
    Part-Lopez, M.
    Guerrero-Calatayud, C.
    Canon-Sanchez, J.
    Montesinos-Gonzalez, S.
    Bello-Arques, P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S672 - S672
  • [47] Tandem high-dose 131I-MIBG therapy supported by dosimetry in pediatric patients with relapsed-refractory high-risk neuroblastoma: the Bambino Gesu' Children's Hospital experience
    Altini, Claudio
    Villani, Maria F.
    Di Giannatale, Angela
    Cassano, Bartolomeo
    Pizzoferro, Milena
    Serra, Annalisa
    Castellano, Aurora
    Cannata, Vittorio
    Garganese, Maria C.
    NUCLEAR MEDICINE COMMUNICATIONS, 2022, 43 (02) : 129 - 144
  • [48] Upfront consolidation treatment with131I-mIBG followed by myeloablative chemotherapy and hematopoietic stem cell transplantation in high-risk neuroblastoma
    Feng Jianhua
    Cheng Frankie WT
    Leung Alex WK
    Lee Vincent
    Yeung Eva WM
    Lam Hoi Ching
    Cheung Jeanny
    Lam Grace KS
    Chow Terry TW
    Yan Carol LS
    Li Chi Kong
    Department of Paediatrics
    Department of Paediatrics and Adolescent Medicine
    Department of Clinical Oncology
    儿科学研究(英文), 2020, 04 (03) : 168 - 177
  • [49] Autologous hematopoietic stem cell transplantation using 18 mCI/Kg 131i-MIBG and high-dose chemotherapy in high-risk neuroblastoma: A single-center experience
    Hamidieh, A. A.
    Naji, P.
    Behfar, M.
    Mohseni, R.
    Talehjerdi, E. S. Makki
    Jafari, F.
    Nikfetrat, Z.
    Hejazipour, L.
    Jafari, L.
    BONE MARROW TRANSPLANTATION, 2022, 57 (SUPPL 1) : 383 - 384
  • [50] Reaching the target dose with one single [131I]-mIBG treatment in high-risk neuroblastoma. The determinant impact of the primary tumour
    Fiz, F.
    Cirone, A.
    Righi, S.
    Massollo, M.
    Amoroso, L.
    Bottoni, G.
    Conte, M.
    Gambaro, M.
    Massone, F.
    Bruzzone, G. Semino
    Orengo, S.
    Sorrentino, S.
    Garaventa, A.
    Piccardo, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S137 - S137
12345